Abstract
The genetic, cellular, and molecular changes associated with Alzheimer disease provide evidence of immune and inflammatory processes involvement in its pathogenesis. These are supported by epidemiological studies, which show some benefit of long-term use of NSAID. The hypothesis that AD is in fact an immunologically mediated and even inflammatory pathological process may be in fact scientifically intriguing. There are several obstacles that suggest the need for more complex view, in the process of targeting inflammation and immunity in AD. In our previous studies we proposed a reliable methodology to assess innate immunity in Alzheimer patients and controls. The methodology is based on the phenomenon of human leukocytes being resistant to viral infection. The unspecific character of the resistance, dependent on interferons and tumor necrosis factor, and occurrence in cells ex vivo indicate that an in vivo mechanism of innate immunity may be involved. The above mentioned resistance could be estimated in a test based on peripheral blood leukocytes infection by vesicular stomachs virus.
Keywords: Alzheimer disease, human peripheral blood leukocytes, innate immunity, therapy.
Current Pharmaceutical Design
Title:The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Volume: 21 Issue: 25
Author(s): Zofia Blach-Olszewska, Ewa Zaczynska, Kasia Gustaw-Rothenberg, Marco Avila-Rodrigues, George E. Barreto, Jerzy Leszek and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, human peripheral blood leukocytes, innate immunity, therapy.
Abstract: The genetic, cellular, and molecular changes associated with Alzheimer disease provide evidence of immune and inflammatory processes involvement in its pathogenesis. These are supported by epidemiological studies, which show some benefit of long-term use of NSAID. The hypothesis that AD is in fact an immunologically mediated and even inflammatory pathological process may be in fact scientifically intriguing. There are several obstacles that suggest the need for more complex view, in the process of targeting inflammation and immunity in AD. In our previous studies we proposed a reliable methodology to assess innate immunity in Alzheimer patients and controls. The methodology is based on the phenomenon of human leukocytes being resistant to viral infection. The unspecific character of the resistance, dependent on interferons and tumor necrosis factor, and occurrence in cells ex vivo indicate that an in vivo mechanism of innate immunity may be involved. The above mentioned resistance could be estimated in a test based on peripheral blood leukocytes infection by vesicular stomachs virus.
Export Options
About this article
Cite this article as:
Blach-Olszewska Zofia, Zaczynska Ewa, Gustaw-Rothenberg Kasia, Avila-Rodrigues Marco, Barreto E. George, Leszek Jerzy and Aliev Gjumrakch, The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy, Current Pharmaceutical Design 2015; 21 (25) . https://dx.doi.org/10.2174/1381612821666150710144829
DOI https://dx.doi.org/10.2174/1381612821666150710144829 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Phytochemicals for Human Diseases: An Update)
Current Pharmaceutical Biotechnology Translational Molecular Imaging in Drug Development: Current Status and Challenges
Current Medical Imaging Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry Advanced Glycation End Products, Oxidative Stress and Metalloproteinases are altered in the Cerebral Microvasculature during Aging
Current Neurovascular Research Acetylcholinesterase Inhibitors as Pretreatment Before Acute Exposure to Organophosphates: Assessment Using Methyl-Paraoxon
CNS & Neurological Disorders - Drug Targets Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo
Current Alzheimer Research Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Clearance of Amyloid-β Peptide Across the Choroid Plexus in Alzheimer's Disease
Current Aging Science miR-132 Down-regulates Methyl CpG Binding Protein 2 (MeCP2) During Cognitive Dysfunction Following Chronic Cerebral Hypoperfusion
Current Neurovascular Research The Role of Apoptotic Pathways in Alzheimers Disease Neurodegeneration and Cell Death
Current Alzheimer Research Quinoxaline Derivatives: Novel and Selective Butyrylcholinesterase Inhibitors
Medicinal Chemistry